Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Holvoet

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Gastroenterology|July 19, 2020
Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized TrialTom Holvoet, Marie Joossens, Jorge F Vázquez-Castellanos, et al.
World Journal of Gastroenterology|June 22, 2023
Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysisSofie Ingdam Halkjær, Bobby Lo, Frederik Cold, et al.
Gut|November 2, 2016
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trialsPieter Hindryckx, Barrett G Levesque, Tom Holvoet, et al.
Journal of Clinical Medicine|January 23, 2024
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort StudyTom Holvoet, Marie Truyens, Cara De Galan, et al.
United European Gastroenterology Journal|May 19, 2018
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonistsMartine De Vos, Barbara Dhooghe, Severine Vermeire, et al.
Applied and Environmental Microbiology|January 25, 2017
Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in MiceLien Van den Bossche, Pieter Hindryckx, Lindsey Devisscher, et al.
Journal of Clinical Medicine|September 27, 2025
Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN)Tom Holvoet, Marie Truyens, Catherine Reenaers, et al.
Journal of Crohn'S & Colitis|April 20, 2022
The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort StudyCara De Galan, Marie Truyens, Harald Peeters, et al.
Gastroenterology|June 24, 2017
Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase InhibitorTom Holvoet, Sarah Devriese, Karolien Castermans, et al.
Gastroenterology|August 8, 2022
Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled TrialMarie Truyens, Triana Lobatón, Marc Ferrante, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Gastroenterology|July 19, 2020
Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized TrialTom Holvoet, Marie Joossens, Jorge F Vázquez-Castellanos, et al.
World Journal of Gastroenterology|June 22, 2023
Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysisSofie Ingdam Halkjær, Bobby Lo, Frederik Cold, et al.
Gut|November 2, 2016
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trialsPieter Hindryckx, Barrett G Levesque, Tom Holvoet, et al.
Journal of Clinical Medicine|January 23, 2024
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort StudyTom Holvoet, Marie Truyens, Cara De Galan, et al.
United European Gastroenterology Journal|May 19, 2018
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonistsMartine De Vos, Barbara Dhooghe, Severine Vermeire, et al.
Applied and Environmental Microbiology|January 25, 2017
Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in MiceLien Van den Bossche, Pieter Hindryckx, Lindsey Devisscher, et al.
Journal of Clinical Medicine|September 27, 2025
Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN)Tom Holvoet, Marie Truyens, Catherine Reenaers, et al.
Journal of Crohn'S & Colitis|April 20, 2022
The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort StudyCara De Galan, Marie Truyens, Harald Peeters, et al.
Gastroenterology|June 24, 2017
Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase InhibitorTom Holvoet, Sarah Devriese, Karolien Castermans, et al.
Gastroenterology|August 8, 2022
Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled TrialMarie Truyens, Triana Lobatón, Marc Ferrante, et al.
Pageof 3